Syneos Health (SYNH) 1 Nov 202020 Q3 Earnings call transcript

Good morning, and welcome to Syneos Health Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

everyone. morning, Good our the Executive on Michelle are Macdonald, Paul Alistair our Solutions. With Jason call Meggs, Chief Colvin, and Solutions; Officer; of Officer; of our our Clinical President me Commercial today President Chief Keefe, Financial

important our release, purposes the results our our including expectations, any on materially slide under results regarding a December presentation at them. prospects, plans, about by factors. the Private our filings. discussed company, and those for regarding future Safe Litigation of from result are of other the investor.syneoshealth.com. and the and XX-K Act Remarks the the growth, Securities XXXX, section In impacts Factors' forward-looking disclaim prepared press a corresponding is financial to may SEC Harbor of remarks obligation addition Actual XXst, acquisitions Reform a expectations its in statements differ Risk pandemic, to make completion recovery These of our anticipated by constitute available subsequent we and COVID-XX XX-Qs forward-looking website indicated factors these to of year provisions that expectations update as on as the statements for various the and ended XXXX, we Form our updated

operations. accordance and call, and measures prepared measures During non-GAAP to events to replacement discuss with we for transactions which a our These GAAP. of certain considered we effects consider core will outside exclude a this non-GAAP financial in should the measures, not supplement be be of

presentation. would the GAAP measures, measures with appendix now financial like to most please of Macdonald. call reconciliation Alistair over comparable the turn of Alistair? directly a non-GAAP For to refer to I our the

and morning, Good in families are safe. you health your today. Thanks, for hope thank and us staying everyone good you I joining Ronnie. and

our market growth guidance, third increase the COVID-XX. solid with remain delivered innovative a strong quarter recovery results both recovery as impacts revenue expenses of for resilient sequential are Our in quarter virtual was pleased for the Total in an We through third managing by were quarter the the the and operations we the receptivity profit ongoing to financial out-of-pocket outperformance for in due in across and below reimbursable our solutions. slower driven slower in revenue segments, patient integrated was enrollment. which solely with

expectations reimbursable expenses, of reimbursable in of impact strong to line Commercial Solutions' the and the contributing a I'm pleased quarter, adjusted the was was the margin. in our expectations performance driven Excluding strength our of which margins with lower EBITDA revenue for Clinical Solutions' with revenue by during mix our the exceeded our partially expenses. quarter,

updated margin pattern the We expect reflected and over could we provide believe shift benefit in guidance, this to that a continue as structural long-term. this our

We strategy remain robust long-term continue to and differentiated the and backlog our confident given of our strength in on deliver our business, model.

capabilities strength extending technologies commitment to acquire dynamics areas, of our emerging expertise Syneos industry-leading trials our on scale the strong Further this looking we belief increase CRO broad combined We overlap. Health emerging to III, and is on a including and to disease, completed, business deploying of our growth well-regarded If welcoming ideally to believe we One mid-sized lead and Phase accelerate the COVID-XX brand. announced scale Synteract retain the customer space, their where look excellence, around companies. cement market biopharmaceutical create is philosophy II to segments within our in patient an will would leading growth, already conversion last and team in continue opportunity unit to global our Synteract's larger changing an the lives the pipelines. operational therapeutic focus of to small- their specialty improving CNS using our end-to-end synergies, full-service of our These Synteract. in in for to growth suited mid-sized, pediatrics, new favorable sector, segment biopharma support emerging acquisition in including right leveraging in to funding This Synteract oncology, dermatology, given to increases Synteract biotech Syneos performance. based is recovery. limited capabilities, win next forward night shares into position rare this and despite the agreement focused recent Health XXXX, pace their of expect strong family. revenue and aligned slowing amplifying in shared of both biopharma cases have the our we a Phase capture an to our offerings. ongoing strength forward and Syneos We're management rapid cultural chapter to and experiencing consulting ability the

independent have them we the possible of employees fuel around XX,XXX work for employees this our I the to innovation while to customer industry. recent among success each for selection to with continue our highlighted thank world, highest want of award the This throughout receiving every XXXX organizations outsourcing Employer as also recognition one Best we become. the culture collaborative for list. the would Additionally, launch polling on without company ranked based engagement capability, of Forbes contributing our biopharmaceutical by We our the Kinetic and and of been not to have

Now I'll quarter. key turn the to highlights from

period. organization. closed of our Clinical resulting growth First, times in us XX-month trailing times X.X book-to-bill aggregate awards, including and net times for QX of of This Commercial net Solutions' times Clinical of for awards Solutions, the billion an and business brings we ratio $X.X new for XX.X%, X.XX Solutions X.XX solid year-over-year ratios for book-to-bill total to with X.X

the business, For this year-over-year growth backlog XX-month growth improving revenue our period for accelerating to in Clinical strong trailing a growth builds for XX.X% position net awards with and XX.X%.

our of availability increase strong credit during adjusted third, revolving to We the strengthening margin flow $XXX.X robust position $XXX.X facility the for of point experienced and $XXX leverage liquidity. we and profitability with And we million XX.X%. quarter with X.X% basis net further million quarter times. year-over-year our period, generated million overall third growth unrestricted on Secondly, the with operating financial of cash and EBITDA X.X cash ended the of XXX

getting sequential a the third excluding quarter, Now staffing of recovery during We the saw revenue results. second to details strong second with the divestiture of quarter into business. compared of total quarter, our contingent our growth X.X% the

operations when customers, revenue quarter, the over staffing progressive during closely growing continue Clinical teams Clinical investigative a the showed Solutions HCPs balance delivered sequential with with of back growing awards, Gross Our to in customer to remain a contingent small recovery compared transition year. our remote face-to-face to work XX.X% a of quarter of Solutions' quarter awards operations. and solid strongest also awards sites XX.X% third the strong, normalizing divestiture record business. the mid-sized second quarter including segment. for last net our to to very

Our reflecting a backlog were net expenses. expectations awards impacted our changes by in adjustment, for reimbursable

pandemic, the billion ongoing period, net visits. increasing remote This the our coupled our ratio same X.X mix an with for increased period $X.X to in we awards Clinical the of As the operations of XX-month to times. for global expenses these an by anticipate site network, trailing the brings book-to-bill remote legacy lower ongoing operations centralization costs, in travel of driven reduction and

double-digit in quarter. third Our including year-to-date, growth SMID a RFP Clinical record flow pipeline remains fueled segments, robust by across customer

have through for end awards burn a much are QX. won COVID XX existing backlog. with of clinical We the profile projects treatments COVID-related of similar also to These approximately our primarily

than rapid vaccine more that awards, burn profile experienced at end anticipated activity a of we will of COVID-XX. have XX% an the a backlog no secure a represents substantial early meaningful expenses, year-to-date cancellation large-scale Although pipeline less did gross study of as see consequence opportunities. start our adjustment, in COVID-related QX, This of have continue we with the reimbursable additional for and we out-of-pocket a to of Outside XXXX.

for the operational quarter, our they outperformed of had patient our programs strong that have of was vote see expected XXXX. net stage compared growth COVID However, to the quarter a XX-month with Solutions therapies, resurgence backlog best expected and awards XX,XXX XXXX. our high solid period, we XX team than adapting Commercial our Since approximately to Solutions compared also by Commercial believe resulted CRO I billion expectations two enrollment Commercial seamlessly achievement to utilization monitoring quarter growth This created Solutions original recovery. be received expectations $X.X for in across of top with remote of the a recently Commercial also commitment for our cases. studies awards Award end sequential was to to for drove XX sites and by performance the partnership. which industry a This deliver our the relationships. launch We're Eagle X.X%. of quarter, investigative integrated ratio approved third continue times. slower X.XX are also to maintaining customers. a virtual both honored Syneos COVID-XX of resulting third of in across delays the recognizing in trailing total book-to-bill in of Health face-to-face has customer settings continue their the for the of this a notable site fourth for pharma employees to revenue in of X% that and the our awarded applaud countries site consecutive are demonstrates year, selected leadership nearly sites to

evaluate customers light demand timing strategies metrics and update our growth remains broader highlighted of demonstrating me pace the growth, approvals. their provide will operating of in Solutions robust, strategies let pipeline robust by some recent we COVID-XX. the evolving pipeline recovering of even on complexity growing Commercial backlog as customer and of remain market, us and product With macro environment fueled an of position in in Our have XXXX to Commercial key context, We in the beyond, that the product FDA-neutral confident that months. strong rapid the the

level sites, continued teams sites clinical physical improvement with of of to in about Our now access their some XX% visits. investigative steady permitting to physical see

remote previously However, than anticipated. facing some mix monitoring are constraints we of higher capacity a visits of requiring sites these

activity, site of only XX% of remain of XX% our leaving sites Another accessible remote inaccessible. some about via level monitoring

least While cautious end. amid around to continue still in to year expect we by our at generally of localized COVID-XX XX% somewhat degree some increases to be physically sites sites accessible be cases,

customers adoption reimbursable the increased visits into lower terms levels possible. visit continued where expect These and our a in to also dynamics both be should growth to the higher offset to our of site percentage margin. in fourth XXXX, more of supporting by efficiency compared revenue and remote sites future activity, a of EBITDA accelerated visits pre-COVID-XX expenses and expansion somewhat as technologies, have of create efficient reduced monitoring of adjusted quarter evolving This their headwind revenue. We remote our represent

enrollment levels. patient are patient both teams also new at recovered the and new are level and improvement in during clinical the of to of Our pre-COVID continued levels trending enrollment The XXX% of activations XX% pre-COVID site new trials. starts experiencing has of pace October, clinical about

While in for clinical when XXXX, recovery and recovers. enrollment trailing activation pace impact the we patient strong strength revenue a to foundation enrollment in early recovery provide site expect the in will fully of the beyond, growth XXXX

permitted large customer, by Our physical of and XX% territories. their the pharma divestiture again omnichannel of visits the visits of FSP levels are now our expect staffing on to The remained return resilient, this of currently Clinical approximately varies into customers return as year-over-year a Commercial strategy reimbursable Within HCP pace We in-person visits areas. with growth, impact customers these to by experiencing the COVID excluding XX% our their field in gradual revenue taking to back stance continued and teams on some allowing field our teams in a business. business increased have to our Deployment of certain teams of conduct have be Solutions' about contingent Solutions, cautious their experiencing for to has physical execute year-end. expenses

be analytics However, given for believe therapeutic interactions, teams certain approaches the no virtual required historical of our areas success to branded as promotional HCP expertise is agility effective. now science our leading fully advanced we that is by capability and deployment to we advanced technology field longer Kinetic, behavioral in XXX% further our and access that that combines physical data, omnichannel our This engagement. have optimize

startup more reduced interactions of the of rapidly Deployment driving communications the HCPs Solutions, we practices of their COVID, delayed hybrid COVID-XX from primary Within of are seen have impact to with now be expenses. seeing evidence continues programs, virtual into and these in customer prescribing effectiveness compelling revenue reimbursable incorporate behaviors. During new the along

public advertising, to Our collaborating and increased continue continues Communications see communication win demand and have across record pipeline we a integrated business solutions, to relations for by projects communications. where currently medical

backlog Our quarter. practices landscape with strong well, commercial perform fourth of entering changing diverse also clients to consulting a the the our continued work helping navigate

over I Forbes around the we've accolades, wanted Before the for to the again, only team awards quarter. not our for the numerous turn globe call to I Jason, recognize the last collected Eagle over once but and

We additional to Jason? together, will have performance. continue demonstrated comments we on face the our execution while customers. providing our resilience, excellent COVID-XX culture focus now provide as challenges collaborative Jason of for financial our and

and Thank morning, you, everyone. good Alistair

me thanking Let a solid up setting growth start and XXXX beyond. for by team for and third the robust quarter us in

our how our Given flow, had growth, our value unique to customers and gross operating we the across profitability headwinds, and including financial demonstrating strong awards, to COVID-XX team our execute. proposition metrics, with resonate backlog continues cash a quarter and continues

and X.X% third XXXX $X.X quarter XXXX of constant the for on in billion, an third X.X% down the to down quarter of adjusted Our total basis. was compared currency revenue

the Solutions' Clinical X.X% in million, constant $XXX.X for third quarter or down was revenue X.X% Our currency.

of impact revenue of was XXXX. X.X%. business, sale Solutions' And X% of third compared Clinical down the grew contingent expenses, our the to of Clinical the staffing Solutions' reimbursable the Excluding quarter impact revenue excluding

response travel Clinical Solutions' our revenue expenses, and to reimbursable we of impacted and capacity somewhat to our remote as our and in customers anticipated than to investigative enrollment recovers near-term expect forecast generally continued visit forward due expenses. adoption lower sites higher site maintain these were Alistair highlighted, activity than of more more by levels reduced was which going increase of to lower remote anticipated. visits constraints and than slowly lower their expenses costs as driven These As be patient remote site was investigator monitoring. Further, be

with $XXX.X down currency. was Our as XX.X% reimbursable third a team was decline to project impact the in decline due lower expenses in Commercial travel in including delays in revenue well or constant disproportionate field COVID-XX, quarter startups. investigator as Solutions' reduced of associated million, primarily XX.X% Commercial expenses new and revenue meeting The

Adjusted in excluding reimbursable Commercial the The ForwardBound Solutions' in lower a and adjusted representing our adjusted ahead quarter revenue cost reimbursable increased to of EBITDA expenses, points. came management expenses. of initiatives, and XX.X% X.X% increase EBITDA basis year-over-year result for expectations. EBITDA margin third XXX and of our Importantly, increase down was X% $XXX.X was million, the an of including margin

of year-over-year, our the XXXX programs, the temporary of quarter COVID-related of XX% over by quarter cost expense. into are which the savings lower driven adjusted of from EBITDA expiring diluted by are about XXXX. interest reminder, and third fourth course a As expected increase XX.X% resulting EPS the in primarily majority and Adjusted for $X.XX increased

cash Now and to the balance flow turning sheet.

total of generated days. in DSO third and We leverage the times. quarter, of flow. of the million the ended unrestricted cash cash our X.X with XX.X for in resulting During operations billion, quarter $XXX.X million was debt quarter $X.XX outstanding $XXX net

after facility term expanding by $XX $XX we Loan B October conjunction of offering and $XX.X its million quarter, our Term in equity repurchased the by September, the AR until and During sponsors in private we Further, our XXXX. extending of shares. secondary million with Loan our million our of A $XX outstanding repaid our million Term securitization

of XX, of this end utilization share authorization remaining had we As million through September $XXX.X year. the repurchase for of

capabilities our As best that of evaluate fuel the growth plan, continue to our our and expands through M&A we position. part market opportunities value creation to our

and earlier, bolt-on of customer outlined had acquisition Synteract. announced biopharma via Alistair capabilities and Synteract an fast-growing last acquisition model. emerging inorganic strong As that its driver we growth a operational night, important delivery the base represents

of the to to reflect our XXXX we target adjusted to X.X X activity. prioritize leverage net to continue M&A While end times deleveraging, for we

the to we third rate for expect tax maintain year XXXX. and the rate effective was that XX%, quarter for non-GAAP full Our

approximately our cash Given the for benefit expect million. outlay net of taxes NOL we be in deductions, actual our to XXXX $XX

Turning XX% higher including related the now currently guidance. we to the company's although within access now expect impact represents levels our factors COVID-XX remote return the to XXXX recognizing activity. of estimate a Solutions XXXX, COVID-XX, expect and our are This of best to efforts to by control. monitoring end on We of duration, to business, our Clinical of severity site mix normal approximately outside the our of its guidance

Additionally, recover experiencing we enrollment originally slowly new we anticipated, site in the expect patient to lagging recovery than more new activations. are

in strong HCP we to the primarily Solutions, revenue of recovery, normal both we impact pace our trends segments, expect Commercial changes end Based $X.XX points EBITDA in reimbursable now adjusted of in That XX representing expenses XXXX expect an had in the the expenses. return across with expect range an access For to cost of million XX.X%, to of range approximately from to on XX% on billion. levels $X.XX adjusted the now revenue management, year of lower reimbursable up XXXX. basis by now $XXX said, These XXXX. recovery $XXX have EBITDA full of we total million, margin billion

Lastly, our $X.XX outlook midpoint. expect provide also adjusted our EPS fourth year-over-year Synteract updated acquisition to guidance the This guidance. the we expected does XXXX to at an our reflect of of closing. our on to updated as $X.XX, not up diluted want of I early growth expected compared pending XXXX midpoint in quarter

the and billion. of backlog including This we add successfully the enrollment revenue completes our patient strong this strong growth to our total revised our to return of This year-over-year growth currently $XXX With XX.X%. XX.X% segments, XX momentum and to outlook earlier also a Note, million current site trajectory opportunities, revenue strategic XXXX. a outlook margin reported will business the with visits. levels, $X.X Operator? to we we decreased staffing to prepared the growth of excludes Normalizing to that remote in basis of the This XX access on to of and XXXX we'd use COVID-XX reflects estimate reflects contingent as questions. and in pipeline ForwardBound of of continued acquisition program, field pre-COVID based our million if Synteract, further growth of $XXX in closed, rates our this revenue year, XX.X%. remarks, increase happy along answer across progress this assumes XXXX. recovery of upon which, any restrictions continues expect expect to awards returning billion to expectations, success Given in continue sustained our the and of divestiture and for be growth both points to team our XX.X% monitoring $X.X

Thank line you. first Goldman Instructions] comes Our the [Operator from question with Sachs. Robert of Jones

Your open. ahead. line is go Please

Great, since Thanks than travel understand to good more some morning. noise be on I quarter. I just for questions. bit expected just it guess to to wanted little a this start you the Yeah, obviously and seems this reimbursable the others maybe causing for better.

to mentioned I that in the XQ on the travel in How as what's number? headwind the for share the And you XQ? this bookings reimbursable impact point was So compare And does around guide? guess can headwind what you then revised anything basis XXX similarly that assumed the far quarter. as then

Yeah. Good It's morning. Hey, Bob. Jason, I'll start.

when XX% you about sort direct be the metrics to year-over-year. the being performing proportionately. roughly you you improvement, you patient original into little we're down you know the to thinking fourth So across in company. in then the reimbursables teams based Commercial up were And when the our Quarter and bit we XX%, approximately improving, you little think it of And but you trends performance set in and you know of you there the of in teams see know you when better a with we bit was guidance to field, of reason you visits similar was in quarter, amount a actually the that have still from enrollment sequentially similar performance the and actually year-over-year set field of number do the And the contraction know now on so on-site the revenues plus. offsetting from terms Quarter Clinical, know the X That's see and look worse for remote, XX% expectation but a in and know then that's X, know that's in closer know field visits we field getting the XX% of we August, doing our XX%. better

- backlog we're the different about in just we that and you would book-to-bill think just So on adjustment, backlog the clinical, When in again. with clinical an quarter trends have you but it's of it's what improvement COVID we if our that - north know expectation know you right than been it's based had really the in sequentially, seeing now. the X.X, the the adjustment take you of out

at good we it and know we know something you don't And about impact and it you what feel So in business having. quarter, the We when bookings was thought our that we you the yet are had. seeing? and know, we was good hearing are a have it about know you others looked COVID that

in going So happening we and bids going our our and operations out in monitoring remarks, mentioned that terms project backlog at the work it's know Syneos focus. non-COVID and we're in we have thing picture seeing remote in the networks. prudent that's on the go what level our of know being see to based and felt you new you what what's forward of and know of the experience level world, we like we're down, most we're ahead the the And adjust going centralized clear sustainable study believe more in to as that's we seeing you a prepared given

said really Okay. follow-up, No, then you just I a bookings XQ, in X% COVID. of And COVID-related know came Alistair maybe work. the from guess on about helpful. that's I

downplayed it been little year-to-date, XX%. and of you're an than the you I a greater think it's as now company, for saying opportunity bit, kind

that bookings vaccine up related treatment that X,XXX know a as there's estimates change Syneos COVID-related share there step and or work could of trials work viable is out over the know you view implies Any to in It just that clearly, seems know. wondering of going be I'm COVID. you So in like rough ongoing. pretty getting you COVID-related there's you big a a sustainable you XQ category? how know greater know -

it's Yeah, a question. Bob. good No, good morning,

I think look at in you two it have ways. to

You treatment to hospital we're the ease you look you COVID that how people with at work treat COVID, from symptoms, COVID. know long know in with know we people the people recovering on, trials working how

I think the profile because profile a a treatment of period et for of cetera. the to a treatment going you trials of the and have looking the longer people treatment already very et need know it those different it, you - trials impact around the antibody while caught you a vaccines cetera, be to know on you and for you the the who follow-up for vaccine on is reaction. measuring have than COVID effectiveness And purely know they have know

I robust. is you know So, that think

I think of we'll see that. more

pipeline of you good investing the suggest side. work, treatment a know in which have that on more We that would know are you people

right work at end have of vaccine QX. more QX, in the We won

customers get flow see work. support of field, earlier that Commercial some the the they support expect educational And also we So they good et we're how cetera, medical treatments parts work, I drive do RFP how meetings, field, on to us in into the to for communications, do people, from their MSL as starting the activity XXXX. side, mentioned, an on in actually

a now. it's more for us balanced yeah, So bit

- is as backlog thrown over blanket underlying the COVID has you who in Jason a I broader And what said, history vaccines we kind than you a the early of of the seeing does the missed know. Syneos and way, wave. our a The CROs you're in without kind on numbers know stuff without vaccine much Warp those have to in top. that COVID think was bigger out on Speed allocated effect big

So, we But again, on in QX. yeah, side. in won more majority the QX treatment of than it had we sustainable, was the

great. much. so Okay, Thanks

Bob. Thanks,

Thanks, Bob.

next Thank the Baird. of question our comes you. Eric Coldwell with from line And

go is line Your open. Please ahead.

much. very Thanks

I'll with Synteract. guess start I So,

that think $XXX found million. the paid I we in XX-Q you

year, pandemic, curious expected. pandemic? the how give I bookings it early sense before revenue. You during have if was closes growth to million held they And represent incredible would months, a the a I'm $XXX company growing said but with revenue up on they kind last of have in call as - million can if let's in for Is potential held six the that back you $XXX on to very growth the the what going strong how up know us say? Synteract? that that of over

Good Yeah. morning, Eric.

for long have obviously. known Synteract we a So time,

We market. are know really well on penetrated we've business that to that while, have connected therapeutic relationships, in They you a organization for a growth. and area focused through impressive fewer watched very really and that

well market You know we've it's a going It see incredible They've very that's responds money an amount We're which funded. very to held biotech seen up well funding, you know very through into. COVID. quickly of to pleased that.

base, to other know little CROs, and of being seen the cost able their a I capability adjust to mid-sized their we've speaks know operations bit you cetera. that way operations, was And remote. through think switch to Syneos than some I move think changes struggle more to remote the COVID et they moved did, to able to same who you the made and it

impressive So pretty is Their it's still hot. growth group. an rate

new they winning I terms hard in think awards were QX. in hit of fairly

You know the people SMID. you and it's sector I QX, few they're know think QX, at look in And saw think And bounce that quite a great hot. pipeline. got you really is that. good to that I back.

higher hotter subcategorized the that we don't SMID the appreciation customers to then really into fact really And mean end multiple for and has traditionally or we've and sales in SMID biotech it we've the just up us higher SMID, on of Synteract great sector. grown that the which people hotter. have of it. penetration, pipe their Syneos getting I As mid grown products, two QX, and - that - maybe record see is with record into we in hot that kind market, for we've and for was of in overlap of emerging QX. the is where And have of that where with grown kind one the sector kind we of lot kind the played the SMID, a segment in has as it's a

their to cultural already. fit relationship having with and So land team able executive a been Synteract, good

You brings give right know we're they biotech, CRO. another model know is their with to they going after globally, to go a free hold it and that it that to business support as people you and Syneos a partner unit have they that specific you a a because separate win now project part know in territory, have then emerging of don't the that's out

gives us as good revenue well on an their it opportunity of growth. So drive synergies top to

is reported curious seeing and to that That's - the comments it's think was X.X total X.X, from I'm if for our Clinical, exclude adjustment passthroughs above heard in might? what would - it side simple other know on I as the the as in what great. as you if delta that Would know to you have passthroughs just some here - seems net the on been book-to-bill some taking simple Or would be we there backlog that adjustment correctly. you it the backlog as was? estimate on be the math I math needed The that if might

that. let a not Jason I'll basically, I'm stretch. complex but any would Well, on thought yes be mathematician my answer, by

let I'll So Jason -

Yeah.

sure but other - than think passthrough kind revenue what let's from impact, not getting of say, any I'm the for the it's I I'm internal expected, adjustments as made to, lower you if

Yeah. it's good good hey No, Yeah, a Eric, morning. Eric, question.

sort about functional there the direct You're think type you as performed know to what right, impact. actually, is short more can evolve reallocated. about you a remote you revenue, more there are answer. When the gets be proportional That's just before, And lower services far of that when talked that monitoring, we've you see yes.

of or So point. side direct sort the the at impact on this acute isn't needed

Very COVID Last the a you XQ clarification. fair. that curious on say COVID-XX I'm you a Number I said awards, programs, award therapies. then after And XQ? two won bookings? for contributed vaccine quick launch believe, won in or to just large-scale one. also one, you if that integrated Did you

more you a if So can give little there.

both of your statements, Yeah, Eric.

take and and that side, program, treatments little to vaccines with the on in an and to we yeah, who - of end offer more to And package anticipating on expect developing QX. to then working that know, to move terms of because got QX, award revenue the of So people kind get service support in we vaccine and that right QX proactively quickly. and you in it's we've large you them launch know at line know QX are Commercial going been bit a obviously, starting contribute then a integrated

and more you the as then backlog some vaccines are the will you right, in still us the think and These lot we field, growth fairly We are a in treatments monitoring, we And through have and the nice the but side, the are 'XX. nice caregivers on give that some biggest some go treatment 'XX the that community. got straightforward, complex of that engagement because to with know of - immunoresponse.

field the I we making positioned So supporting well MSLs sure training have products capitalize on. be think the those are available, centers that something materials call in to that we'll there, is out are

Hey, Alistair the will parade to the very CROs But to award vaccine I seen hate last be taking promise the in bookings. XQ, steal this approaches follow-up. here. we've different I

some with passthrough Number of those CRO with tremendously, one. of have all passthrough streams number high those actually the and Some it. doing are two, doing others are very or not awards coming the awards discounted coming not

little So bookings passthrough color Yeah. that just more maybe core ex the comfortable to get us clinical a on adjustments. with

perfectly to for, Eric, very bookings what conservative We're on Yeah. took honest. into we be

our the a regular and it's we pretty QX. bookings looking wasn't into COVID SMID I huge I'm customers, the policy, from So of with on under but overall on production know took a significant you regular much mean, a XXX% in quarter we the you it had what sure it, overlay top. amount not know

So trial. of - certainly took vaccine not out in near we conservative that nowhere awarded we were it's biggest the in thing were It's quite we what that certainly QX.

So the need you color that. hopefully, that you on gives

there color additional little Yeah, little on that. Eric, provide a color - to a just

of some the You that know have in et see the terms we trends ratio seen of the similar you know that did bookings, cetera. of others

hearing we going we we're So this run customer way the et looked it's - Do if okay said, to what did we What's this extent. know cetera? fully timeline, on see that to way, that, it is structured? did believe what the we and at that you how it discount today we you and based what look at from the and some

of the a was during direct. component on it passthroughs However, large the quarter with less

if going lower look far than you bookings, you know said you that. and So know impact to less than at be is we just year-to-date the our direct XX% to

just until coming It's that. seeing through up and are coming not we XXXX. So

much very Appreciate guys. Thanks it.

Eric. Thanks,

comes And our from question with Dave of line Jefferies. next Windley you. the Thank

Your Please go line ahead. is open.

my Thanks on philosophical patient comments. kind of of morning. questions. taking good A I think ones. One for couple Hi, recruitment the

you think and we as know is would site things learned for But to you the contributors, know we trial, has horizon so you revenue about lots revenue know a in revenue. comment far a been not you more access, recognized other more do. have that you longer-term all don't how different think know CRO I I than the type if requires of ever don't thinking, we've and detail thought this have you year patients

in does there. so that the push Obviously, good forward But value impact these seems studies, Alistair. how you duration your of I'd patient that, to studies, demand of recruitment to comments on forward? change to wondering some move recruitment studies? know about be your I'm change curious about in of and appetite clients' be your thinking impacts how so seems thoughts desire And book-to-bill patient

couple over we and think larger of projects good a that of Good talked a we of bit the It's kind morning, you the I Yeah. last question. the run programs. mean earnings. It's - I Dave. part little thing are know same about

of looking at trials of people what still XX% We're say, So I right. do COVID, are XX%, are philosophically of the enrolling, think at we impacts COVID, pre-COVID enrollment. levels

So than rather be every delays to the study. specific tend enrollment in studies

right some are So on it. studies

XXXX, of know COVID at look you is I of because you they're willingness a a falling That's people it, people into in patient And go But program. think basically know study, project and behind it. to their - got the right. somebody's hope accelerate going be we through approved ways got doable, got philosophically, work that's of to program we've within that's get when studies if kind out let's the program. to site. Some the this And affecting the to I don't, be the believe, are rest will a say, - to in and

any and You sites? coming got I that's going in this years “Look, So want to - to I time. on time I study that in XX% need know people have a my the studies saying, how still we there's and see you take might project take doing. do I program long want do. XXX accelerate going you think if cost you've I of trade-off And study got is it through sites, or keep to XXX it?” me if How can a three

it think at I way. come people will So that

You're absolutely right about enrollment.

done et management, in The be for needs - obviously, the without study. the project get know monitoring getting revenue, You cetera. on cetera, that a our patient to active fees. a the the and mean revenue keys engagement et sites, open lot et the But sites of cetera, off a I patient patient, you from data being et with analytics, cetera, the of management

That's are philosophically know you around. conversations are think with customers customers I people had where where We've our that's at. So, at.

about program of You a rest know of program up obviously, project COVID level the we Does do know you sense? their how program, accelerate, make do got the itself? because by we if awards, how we're delivering that the shortening whole to delay we think

you. yes. on it's the It good perspective. broader Thank a reminder does, Yeah,

client The mid, in it the general. I level, legacy certainly understand second maybe more small, you at is Research smallest little strength INC I the on you in want to M&A. touched a for to - specifically think on the but question biotech try that has

here, as already for yourself? so And think add What that in does you question kind of you specifically you into you client build, seem versus is, have about grown that be M&A buy - so the Syneos couldn't of to kind base. Synteract basic

grow Well, right. time. over I you're could We think into it

our customer in There hundreds get but of customer and a of customers we smaller emerging overlap. their - well when customers you through become at that of As relationships patch none. that, biopharma, we've know their Synteract plays, become to bigger that the maybe we we territory. with is virtually a - there's SMID where bigger, list that no patch themselves. the with companies And huge virtually develop I we SMID, little biotech emerging bit, And are went that end them, it's list, tended that look diligence the when think thousands can't There to.

So expand helps it into that us patch.

their sector. their can you when think BD into expansion bring look of they terms an and touch SMID what efforts I in it's at our team, that customer of

of X%, think I has that think of sector. a from our we know - of revenue that little the which our sector, bit, kind comes away organization grown emerging only you out I

an know more service opportunity gives You it to there. us customers in

financially, into legacy. fast-growing, biotech that the broader penetrate with synergies set and revenue emerging offering grown INC's And we've within those it, as a organizations we history. cetera. you - that smaller, the have a developed, less you us you these kind think as strong know you them Syneos One And because very for and it's infrastructure, tended of that for I are of have methodology say, are sector really to larger et know One drive was to revenue know and that kind to we've that, like. don't fit our we've reach, one extended synergies chain up for Syneos us which winning issues our end like, their Synteract, But take work, of have as the from of customer SMID us you to larger being the able enables that well-funded geographic if to deliver they is you with behind develop if then

comment quick to integrating? opposed a them leaving And stand-alone on as Okay.

working with know about working mean large when if I business as units et our Yeah. our are stand bigger integrated the they're armed and with they dangerous you think pharmas, processes you they now, companies, cetera.

of clinical a we bureaucracy the into part Synteract engage encumbrance focus has - but to the be by of merging unit ability it I want that want that lose quickly without with mean, to be customers obviously, will CRO. that a it nimbleness, that massive of stand-alone will offerings, don't that. to our We So

sure that horsepower emerging So we but to for bring we when the give stay don't we focused behind sat that keep them want it. freedom and that them and in, biotech we then we it it, while to need them make break that having nimble they ability on

Got thank appreciate you. I it. it,

that. little to just bit Dave add and Yeah, on a

the So we to about are of you think back-office know you going functions. integrate some or enabling when function

cetera. with network, So the mentioned. et for front of integrate to with makes to managing the go business know end, independent there that keep we the we customers, normally want we going market, into when know you and our portion dealing to side Alistair will reasons do, projects, you operations then about But will think some that the as be you sense

that's it, helpful. Got Thank you.

Thanks, Dave.

question Thank the from you. Suisse. And our next Erin of comes line with Wright Credit

ahead. open. Your line Please is go

this is know a be aware I but margin this CROs, kind at there. higher smooth. thanks. or assuming given with have core when sort business from to be an we relative guess it's two of inherently that you we And do of of you of want don't with acquisitions not though overkill Hi, sort transaction? are any that then across core should there's to it the As always follow-up I here I dissynergies combine your primarily want focus? the I biotech question, limited not any to also, sort of. dissynergy industry make just sure

Yeah.

answer very is quick. on dissynergy the So side, the

Because You of - we know in at I the is and the lack answer look mean terms really the coverage have diligence any. of really overlap you things of one in is no. of customers, don't closely the

know the they very Syneos They're lower SG&A we're think you their margins for because slightly I of happy bring the up level. margin side, load. is us - So the goal their on that. we to with Then - to

back at. of So bring as that with help them we you know more in to end, up some integrate where margins we're to we hope work their line

should consulting it given across there? that the on then volatile bit can how some And little drivers but quarterly be a about dig quarter-to-quarter. the thinking we Commercial stronger of versus in segment, be headwinds perfect. segment Okay, to the communications Thanks. into segments, You mentioned progression want

Yeah. Hey, Jason. Erin, it's

sequential see expect we to Quarter in there to continue growth So X.

beginning to As you us. know and projects - you has win August encouraging well for has business held our really know know in we the to you outlined start, guidance, and at been continue are which up

expect as it see thinking year-over-year know growth sequential 'XX at getting moment. well that at about to improvement we into sequentially then up we're is you into point, that So the how and

Okay, great. Thank you so much.

Thanks, Erin.

the our line comes you. JPMorgan. Tycho of Peterson from next And question with Thank

open. line Please Your is go ahead.

Okay, start thanks. some on comments Alistair, of recruitment and I'll your up with site on access. following

capacity sites that of XX% talked now allow majority Is have that You about still of constraints? sites but have constraints. visits, you the know capacity

it's good think I a of proportion them.

I think about it's evenly. pretty probably split around XX%. It's

some to sites cope able restrained. more else physical through sites and anything are Some than just are space more

know it's locations. multiple you very hard on So hard site to get multiple some monitors days. in It's get to

really, a a Tycho. it's bit of bag So mixed

think flagged us of Can know know at about And couple you out what currently you've times. just percentage you delayed point? this are maybe help your trials then you and delays on the of a

Tycho. number. you good I question. it's But that by don't we I handle not potentially. it, on. can you I'm know therapy. a a if It's know back on you, that Paul have on don't, Paul, more sure to we get If is have

on obviously, you up lockdowns. weren't catching know patients oncology. during the know you So first we're We're obviously; clinics going into oncology

delayed, are dermatology of up. projects but catching Some the

them are it some into them be up, of therapy. are did them we unless and expect, some to pretty And hard question dial always faster by of going so catching the and hard some actually are of delayed than it's answer to you so it some will of a percentage, don't - it have slightly have delaying. but that enrolling to But would whereas I think I because delayed,

Alistair, Yeah. I Paul. is mean, this

I just mix country those. therapy, too regional think it's on not and but

or somewhat is not the around patients So answer. going dependent split sites or then all are there's to size that those into one no not. and fits as Each whether indication regional trial on

for then quick Jason, or two And Okay. ones. one

fourth you're you And are related. you know to you of the revenues? talk know leverage in you Or on assuming the ForwardBound? think COVID all from then margin actually to your the XX% guidance as for there quarter, cost we Are here know bookings pulling you you're about know what guidance. able I are XXXX, additional the about Just here end? talked EBITDA for is COVID levers

Yeah. Tycho. Hey,

first you and on revenue, to awards look immaterial immaterial minor. COVID. X, seeing we're we So XXXX, in picking that starting still very X up. Quarter to know it question, in Quarter we It's relatively relative on you but X is the have Quarter ramp really - the to When have

know particularly it like on being those how pretty out. as And play of to you get other? balanced one So - looked that started vaccines what that ask second many we've Tycho, to can terms and know we're happens the know tried the to you again, talk there. you about balanced if at the could please? we've we question relatively be have two However, or on work, in we have, you know you just feel closely you

Just on the EBITDA margin leverage.

quarter, additional You coming are cost levers know from monitoring? cost the guidance is the your all for you there you're lower the ForwardBound fourth pulling was know that question. for remote here? Or and That

Yeah.

expense type your on orders, is side, and you - and the then Quarter you sorts side, you The Commercial you risk you Quarter on strongest and that make the continuing normal ForwardBound on fee things. your X it's progress of side. really vacation contracts items direct seasonal we on on see, out whether you X is change it's the And taxes in PTO seasonally have continuing quarter, know know always changes. know share items these to know cap right, our So margin revenue

driving that those things are really it's that So, increase sequentially.

just about starts on then fourth to for Solutions? reverse you Okay. Commercial. do that the Deployment in You backlog think should How last And we think one know the quarter? decline in

Yeah.

haven't we So we be, cancellations. the us, COVID for their That seen and Quarter are cancellations in see Quarter to we front strategies out did you things, us to or they - X, COVID have allocate while want been you on that in that side, portfolio, and been in Deployment how and start put a Solutions things know moderate whether at know you might experienced and continuing of have some to decisions happen funding, of meaningful it's is know their it X seen canceled right that whatever beyond. looking where that's they're have pushed it's we changing divot product delayed, it

looking next We at year. have good pipeline. We're

We and pharma for launches have you that's we partnerships bookings in top these COVID we awarded Quarter the any Not were talked now of the side. that have X, yet. really in about integrated on our two XX the know

in you Quarter at So X, Solutions' know as those do to where or need we but grow on like look be our opportunities, pipe growth to see come we Quarter start of have forecast. that do Quarter really, we expect to to the that. X it's to Deployment see backlog good feel a And the X, sight in line to able we you drive to side

thank Okay, you.

Citi. question from you. the line our Donnelly comes Thank Patrick And next of with

open. Please line Your is ahead. now go

expanding Jason, just maybe that on thanks. piece. Great, last

Commercial more just Clinical you can 'XX a we know How give guide, You Commercial, you little of we know through when talk at progression? should and look color kind about versus it the think the right are just sure growth year? the side through side? want the we're particularly ramping of I thinking both assumptions on kind conversion What there, to and make about there. the made

morning. Yeah. Hey, Patrick. Good

you of strong both and businesses. when hit you the Alistair know we're So, think this, on seeing about businesses, growth growth the in

you given is what than a on stronger the about. that growth direct and side we've year little talking know the Next reimbursables been

to growth side, perspective. quarter that come again, on X.X% aren't that you it year-over-year to little nature the and and the start COVID and mentioned to Deployment in you on at rate, second side about from vaccines side when out Erin, know throughout first that these Clinical half half. Commercial than you So, the know progress the will from feed we of expect have on that know start you to that you the and know see Solutions in with we the I will yet continue the see backlog in you look know a half we'll being burn like beyond. up on first that be things thinking know to then balanced being And you the second lower opportunities earlier to there year

you and beyond year, really build know start expectations. know in the and this and there, our have continued well relative growth to So backlog, to consulting we'll so to and performed Quarter have pipes X you communications show strong

we're then XXXX. obviously midpoint - a how So which you the you XX on of that from know you know from those And And the we're to continuing up to XX Synteract point to And there. know thinking assumptions, focus about obviously, need in we're XX basis XX.X%, gave is which high-level that that's basis points XX.X%, on layer it. kind guided side, to we margin of we revenue progression. we're to

how So thinking about that's Patrick. we're it,

thinking how color. you've Yeah. No, much of XX expansion temporary I up cost on know that's I to - which helpful. the the guys And given of expanding about margin makes XX. just made? some should you side, this quickly be good How have maybe reductions appreciate about you year. know color that the that we

what expansion? next up some much back around costs how that to Maybe talk year? know come You those of XX XX through makes of just assumptions

growth. you Yeah. Well, know obviously it's

leverage delaying have I at percentage that come done, know you of of like the things COVID point. adjustments a business as start have from don't about to to you by things think get that, being promotion-type underlying reduction. items and offset compensation the back back. these we and the coming expenses made, out know recover you of growth travel to year revenue merit So necessarily down, some continue the we This this offset other we they

know still through budget. the You we're detailed up working bottoms

the have of sight good in relationship up. a drag in that the we we clinical you line growth to to the talked customer And actually year, all this the standing get we're and know about starting have and we relationships better. underneath However, as this better XXXX, year, COVID, margin that revenue new

about pulling ForwardBound operations we new to other And continue September automation we've up some up. we of ForwardBound talked and forward. And network that And terms then start know opportunity the projects and see our know leverage you standing pulling and you more you So opportunities. relationships it there. is see forward. and talked we and in have to it there pulling in about more

to driver as that a So, you know ForwardBound is key well.

Thanks, really That's helpful. Jason.

And line you. next from comes question Kreger William our of with Blair. the Thank John

Please Your line open. go is ahead.

forward a going Hey, getting expectation to sort reasonable of has I going guys. the And Synteract. back that Question is sort well? pandemic things. know were Thanks. as But pre-pandemic? distorted growth of they what

from mean, growth Yeah. Hey, John. good I Yeah, them.

I had they're the drive of they'd conversion the we're seen little areas those to terms through when diligence power I obviously to sales a into And QX in conversions and think QX focused back looking saw they that know really we've due in helped you think that. bit, pre-COVID. at what

more that. in drive they've we from but recovered like headwind had we're think the capability we strongly it, and can And QX, that I to help everybody's and by very more very them. So encouraged them as of more bring services

in goal? or margin to - help XX XX Great. the hurt Synteract bps allow does And annual that of improvement you Thanks, sort to Alistair.

Jason. over companies, it's getting done you several John, Hey know nice growing job organically, infrastructure know of Those know have you acquiring getting out, years a the last guys the capabilities you built know built little put grow. XXXX has and a we where out them in that for to look opportunity bit are margins to And a you of beyond. us position an their as

it over those grow we drive the opportunity synergies. about have know we optimize to as revenue in, year coming as an think So you more,

the you to but believe not structure, they as Dave, a your put outsource funnel. to their we and at SG&A it Health mentioned when as the know optimized for we can their and then have to into top in strong, - pull as and utilization It's into an that it You opportunity them cetera. know what they et be might just take regular revenue's right, bring Syneos opportunity we things items, make more Synteract efficient and that you is employees. about think but of higher procurement can I it comes our revenue there have Their today, margin. broader revenue, customers

going help XXXX work to will but optimize year over and will time, that, to So be it's us immediate be get to you opportunity know a on to it it.

about, of other much a metrics you words, just the helpful top improving help some that? operational been enrollment the you things for thanks. growth, the terms of assuming to much have at is Jason And Can talked Great, that do early challenging? look really change of line. in you which 'XX you one more. In are monitoring, assuming on-site of The way us in Are in way like the ability understand?

X are expecting through Quarter for you and of once We in, to factored level sort are. then Quarter out. it We've but we and X John, sure, get know starts we improvement

the half, I know that and start these first So half. then today of to second items would out we've you impacted that in say, by about talked still come you

Great, thank you.

And from comes you. Jack line of our the Meehan next Thank with question Nephron.

Your open. ahead. line is go Please

good morning. Thanks,

First, clarification. just a

Speed? large study affiliated the won Operation So vaccine you that in one is quarter, that's that with Warp the

different of that No. way. think geography, well, if - you it to want It's

supported in So government the Warp is know Speed like by U.S. you but -

Okay, Synteract. then on back understood. And

you can margin the profile. appreciate revenue color around that Anything of to profile. I So today? makeup Syneos similar the Is add that around

Hey, Jack, - Jason it's

leverage. going covered can them was or take answer. you leverage as Jason, bring we to I think SG&A margin in more think, you Go know out some opportunity but some yeah, we with on, we I But have it, SG&A I that improvement say Jason.

they've our overall, total Yeah. Clinical know capabilities, at you business the for cetera. look and, know out really, global building in building company, mean reasons you et the if terms of scale, outlined I it's lower been you now they

things their we're with to the able all that. their going investments, be So investments, them, for help to now go-to-market solved know you that's technology

sight to we opportunity So drive to in, line but be be it's going to have that able coming of - that to the lower up.

impact out? was could guidance Got just earnings XXXX it to it. might trying of the what terms I think How I laid guess about contribution. that add in you

it to the in range it it's result in the in what to XX potentially this just after you get how the terms inherent at about all the think would need I in end going XX we of in about I think terms is toward that it. how I it of lower bps. we that know can at could be it gave and But see range and it. being quickly get and opportunities driving of Well, It look to point

Jason. Great. Thanks,

You're welcome. Jack. Thanks,

question Anderson with Elizabeth the our you. line Evercore. Thank And comes next from of

open, is please line ahead. go Your

some Hi thinking delayed FDA XXXX, guys. guidance is could do Thanks disruption? I terms how like think today. or for thinking additional with question more kind the into or like deal opportunity of Or things? in that fixed you work? kind know more as of guys of trials - that what paused of the some terms about we're some type of was of just new have about of price it you fall how some for does that other you like create in And Thanks. been to

good a It's Elizabeth. question,

it's enrollment, I it, in to completion, as be think know deviations, project, piece cetera, project all addressed. have will it's you that to at you know as where overall of et we piece regulations patient terms get waivers, around project considered each by be the almost to its know you need

going you So package project to happened a what what cover that's regulator each be able explains that at go done the was it. affected, of put to and end into together the to to the want that's day,

will that's I do by everybody So project-by-project But will review to that of Obviously, level to yeah, those there's that. be scope covered. I and there. key in scope some things think of changes for are that us, make kind the covered as opportunity additional work be sure identifying think a with on - else,

helpful. that's Okay,

that in to margin ex beat 'XX, you of business the core XX metaphorical talked horse, bps but to yes? a expansion about dead the Synteract, that's sorry And XX

It is.

know captured terms us in, in exactly what range. it get of bringing out However, do about allows being within I the would range. it to think and in to We figure just - Synteract in you that have

Okay, thank you.

KeyBanc. Donald of Hooker from question And our next line comes you. the Thank with

Your line is open. Please go ahead.

Solutions kind gone and years back and over we've here, the I'll I I all call kind have we're of - segment can to of morning. this kind that the or should given think past the - step Great, year next that a down of seen be what up anyhow. there so? along, is of brief, maybe But for revisit expect in just revenue guess tracking know investors five follow-up all parts what is and a kind we so three growth good Commercial over has the a and that moving normalized segment, we the noise

start we at about then Yeah. and/or one Michelle you I'll and Alistair the right and penetration, the business, and behavior the consulting then that communications think the and in. chip team then, where When outsourcing up look outsourcing on Hey, and how Don, Jason. it's know and can it's field consistent and side penetration say, been less customer into has clinical. on particularly goes

with as think X%. we know that's then that X%. we we spending you into space. business the area one So within companies, look that right And know share pharma growing we you market factor I up we and the SG&A you that know know still the in or do it When guess we just It that and focus market that can business, spending happens we at the you the right, might you happens of grow that in time, exactly on. take at can that see have be vast really over not we what that's addressable a

it, but from be it consistent So as just it's how that's the about business not quarter-to-quarter. think as, as you consistent, that clinical we know is could

And wonderful for thank you That makes that perspective. sense. a

You're Donald. Thanks, welcome.

comes And next UBS. the you. from line Brennan our Thank with Dan question of

ahead. Your is line open. Please go

Thanks Hey, thanks for guys. the question.

on with sensitive COVID. enrollment know sites' wondering I'm gave some you how patients of a are metrics Just to just the COVID. question on you

think wondering, be to stocks October, that there's lot mitigate to I a and going lot be a I'm early really up learned, CRO there'd picked lagged of concern would I just since of impacted. are ways lessons cases trials this. have think a

move to at kind just a we trials give around? the for front end is with any way flavor So these you COVID cases watch what us there see clinical of as

perspex life almost? patients versus I it that I the treatment super It they now. oncology on back have They and I May, if as Yeah, critical a in, And death, what - depends you of So we at it they not and the to know put themselves - jab. they long the They therapy. depends difference keep are mask going patient they're know think, sanitizer. because think all on, screens. assurance, in? as now can wearing saw April sure. that on the we're a good Is that to is distancing go go in in kind but follow kind of for comes answer, Don. you the matter social patient therapy. have to social it of sites distancing I''s setup. the extreme timeframe the a going the seeing going a and risk is know It give to have have is you They have - this question, depends

I down slows it and back rather the the like pace because QX a cratering the we hence increase than know a you slow and fight engagement, So next it - And it, I of a - but it expect all markedly, down creating as So like through think I I just will everything plateaus that this don't right? you'll it. don't ongoing enrollment COVID, saw additional back wave come it on we in in timeframe, guide of slower expect - we enrollment think see we - the that it rather passthroughs the anticipate but down. it than pullback some April to increase of March, to for that see - continued off will pull

think it about we right of kind how So that's now.

And there lasting Is back the you just means way out it's are Deployment these probably cost? Got you to any 'XX, what lower of there's you a a beyond it. impact and how other, affected. little solutions? out with hit think but be to is this And EBITDA terms XXXX? little it as bit because Being maybe the through negatively, seeing revenues whether neutral obviously monitoring 'XX, know - look Solutions the a look just being in on remote as one it

Yeah.

I gist. broke general the up the a get You there bit, in little question but

expect think I a to see of remote of remote we and right. monitoring elongation adoption more an future more in projects,

back for you day. can you're on a do - lowers day that and doing a that not you little day back. pulls passthrough it monitor revenue, more remote bit but next per done unit a till units not because is They're the to visit traveling the our right a know They the yield. a visit day. So site remote And the get

can obviously, actually which bit So positive a the anyway. you more there, empty And is travel reduction think just there's in production, margins. is get I a which for expense revenue

down the dilutes of kind which again So obviously. margin,

a So bit lift of again, you get margin there.

So think I there's an ongoing.

Clinical the On those. side, you get

team We've Michelle's christened So proven done more I has think we've of that now fantastic system a omnichannel. the to with Kinetic. job the shifting

of and with to and speak that multichannel a I that the of their they've Kinetic uplift together think in paper seen HCP. a the putting because Kinetic had sales the we're use overall on customers more methodology more Kinetic Kinetic engagement we're engaging, results we're with wide seeing an the experience to as that using seeing system from the

help It's think. remarks be margin, a said of which one to be in the of anticipate to the XXX% face-to-face that think the know know - we we longer in bit prepared - for change in I law lasting, go Commercial So be - now of little I success that a having you and will big of success the a that that time I and will a you will jaw Commercial will sales don't drug. know drive lasting you sales side, pack the the think

Great. Thanks, Alistair.

Thank you.

any I'm Thank time. conference And Alistair the questions for showing at you. to further this over no turn remarks. like Macdonald And I Mr. to further would

Okay. Michelle. Thank you,

all very as So our position. again, on they've remain thanks Syneos confident conditions today a in recovery We to team throughout the building sincere everybody, COVID in done face the entire for long-term momentum of And market our have what unprecedented continues. year. look I been to the from the forward

So be today safe. very much. investment thanks, interest and your Please everybody, day your in and organization. Thank and a Have great good. for for our be attendance you

you the gentlemen, Ladies all a great thank conference. in This for does conclude disconnect. have and you today's and participating Everyone, day. may program